TriangleTYRA-300 60mg (NCT06995677)
TYRA-300 60mg trial for Low-grade NMIBC (NCT06995677). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with low-grade, intermediate-risk bladder cancer that has not invaded muscle and carries an activating FGFR3 mutation or fusion. A small visible tumor must remain after diagnostic biopsy or resection. Previous FGFR-inhibitor treatment is excluded.
The idea: test daily oral TYRA-300, which blocks FGFR3 growth signaling, at 50, 60 or 70 milligrams. Researchers assess complete response at three months and safety. The trial is not for muscle-invasive or metastatic bladder cancer.
This phase 2 study plans 90 patients. Tyra Biosciences sponsors 36 recruiting US locations.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.